BioSpace News Archive

Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced the publication of secondary efficacy and patient-reported outcomes from its Phase 2b randomized clinical trial of tapinarof cream for the treatment of atopic dermatitis in The Journal of the American Academy of Dermatology

Hariri, Gorlin, and Rogich to Contribute Their Tremendous Industry Insights and Stature

EXUMA Biotech Corporation, a clinical-stage biotechnology company discovering and developing CAR-T products and delivery solutions for liquid and solid tumors, is pleased to announce that H. Michael Shepard , Ph.D., an acting advisor to the company’s HER2 program, has been appointed to the Scientific Advisory Board. Additional

Kronos Bio, Inc., dedicated to drugging transcriptional regulatory networks in cancer, today announced it has appointed Christopher Dinsmore, Ph.D., as Chief Scientific Officer. He will lead all aspects of the company’s discovery organization in Cambridge and will be responsible for advancing preclinical candidates targeting multiple oncogenic transcription regulatory networks. “Chris brings

In a phase 1 study, RBT-6 was administered to study participants with moderate to severe chronic kidney disease (CKD) and showed an increase in expression of antioxidant proteins. These findings may help develop a pharmacologic stress test for determining antioxidant reserves in CKD and other medical conditions.

Doximity, the professional medical network, has acquired THMED, a leading healthcare staffing solutions company

HALO Diagnostics released interim 10-year results from its Phase II 20-year clinical trial for prostate laser focal therapy in patients with localized prostate cancer. Over 170 men, 45-years or older diagnosed wi

Perrigo Company plc, a leading global provider of Quality, Affordable Self-Care Products, announced that Perrigo Finance Unlimited Company, an indirect wholly-owned finance subsidiary of Perrigo, commenced a registered public offering of senior notes.

bioAffinity Technologies , a privately held biomedical company, today named its research laboratories in memoriam of Harvey Sandler, a businessman who used his considerable success to support research that advances diagnostic tests and targeted treatments for cancer. “It was due to Harvey’s initial investment that bioAffin

Inovalon, a leading provider of cloud-based platforms empowering data-driven healthcare, announced a five-year engagement with Cardinal Health, Inc., a global integrated healthcare services and products company, to provide a configuration of Inovalon’s ScriptMed® Cloud.